Journal of Clinical Oncology
Articles in this Issue
Effects of integrating palliative care on the uptake of advance care planning among elderly patients with advanced genitourinary cancers.
49 Background: Integrating palliative care (PC) into oncology has been demonstrated to significantly enhance the quality of life for these patients and fa...
Bone metastases and use of bone protective agents (BPA) for metastatic renal cell carcinoma (mRCC): A contemporary national real-world analysis.
490 Background: Bone Metastases (BM) occur in approximately 30% of mRCC patients (pts) with evidence suggesting that they portend a worse prognosis. Syste...
Nectin-4 and Trop-2 expression as potential therapeutic target in collecting duct carcinoma: Preliminary results from the CICERONE trial (NCT05372302).
587 Background: Collecting Duct Carcinoma (CDC) represents 1% of all renal cell carcinomas (RCC) and is characterized by aggressive clinical behavior and...
Exploring the efficacy of belzutifan in the treatment of renal cell carcinoma associated with von Hippel-Lindau disease: A comparative analysis with external control arm.
469 Background: Randomized controlled trials are the gold standard for demonstrating treatment efficacy but are not feasible in certain disease settings....
Surgical variables and risk factors associated with urinary leak following partial nephrectomy: Insights from a high-risk population.
604 Background: Urinary leak (UL) is a common complication following partial nephrectomy (PN). This study aims to identify the risk factors and surgical v...
Racial disparities in renal cell carcinoma histology and outcomes: Insights from the French Kidney Cancer Research Network (UroCCR-191).
442 Background: In the U.S., racial disparities in renal cell carcinoma (RCC) are documented for common histologies, highlighting differences in incidence...
CUPID ( <sup>64</sup> Cu-TLX592 phase I PK, biodistribution and dosimetry): A proof-of-concept study of TLX592-targeted alpha therapy in prostate cancer.
177 Background: Antibody-based PSMA-targeting therapies have potential to overcome limitations of small molecule approaches such as undesirable off-target...
Impact of the 2012 and 2018 USPSTF statements on prostate cancer screening and metastatic rates in Kaiser Permanente Northern California.
359 Background: To assess how the United States Preventive Services Task Force (USPSTF) Prostate Cancer Screening Statements of 2012 (Grade D - “recommend...
Characterizing the activity of inflammasome genes and their association with oncological outcomes in prostate cancer.
410 Background: Inflammasomes are multiprotein complexes that regulate inflammation-associated signaling pathways. Although inflammation plays a crucial r...
Second-line platinum-based chemotherapy (PBT) in patients with metastatic urothelial carcinoma (mUC) treated with first-line pembrolizumab plus enfortumab vedotin (P/EV): A single-center, retrospective study.
785 Background: Although the efficacy of PBT as first-line therapy for mUC has been known for more than 30 years, the recent integration of P/EV as a pref...
Time to real-world progression (TTrwP) among patients (pts) with relapsed/refractory (R/R) testicular germ cell tumors (GCT) undergoing palliative chemotherapy (CT) in the United States (US).
628 Background: Pts with R/R testicular GCT are considered to be incurable, having experienced progressive disease (PD) after salvage conventional-dose CT...
Results of a cross-sectional survey to explore determinants of health-promoting activities among Hispanic/Latino (H/L) patients (pts) with prostate cancer (PCa) on androgen deprivation therapy (ADT).
321 Background: H/L pts with PCa are at an increased risk of developing ADT-related side effects. Diet and exercise can improve PCa-related outcomes, incl...
Utility of extended interval dosing of denosumab in patients with metastatic prostate cancer.
68 Background: Bone modifying agents, such as zoledronic acid and denosumab, are commonly used in patients (pts) with metastatic solid tumors to reduce th...
Recent treatment patterns in US-based real-world patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC).
104 Background: Androgen deprivation therapy (ADT) intensification [ADT + androgen receptor-pathway inhibitor (ARPIs) +/-...
Effectiveness and safety of radium-223 in men with metastatic castration-resistant prostate cancer (mCRPC): A systematic literature review of 48 real-world studies.
81 Background: Radium-223 (Ra-223) has been approved for men with mCRPC with bone metastases since 2013. However, as the treatment landscape has significa...
Efficacy and safety of nanosomal docetaxel lipid suspension in Indian patients with metastatic castration-resistant prostate cancer (mCRPC): A multicenter, open-label, single-arm phase 4 study.
168 Background: Docetaxel combined with prednisone is the first line chemotherapy to improve overall survival in metastatic castration resistant prostate...
Comprehensive investigation of CPSF3's role in the progression of bladder cancer.
829 Background: Bladder cancer (BC) is a global health issue, with a significant number of new cases diagnosed annually. Despite advances in treatment, ma...
Rucaparib vs docetaxel (DTX) or second-generation androgen pathway inhibitor (ARPI) therapy for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 final overall survival (OS) and safety.
155 Background: Primary results from the randomized, multicenter, open-label, phase 3 TRITON3 (NCT02975934) study of rucaparib, a poly(ADP-ribose) polymer...
Androgen receptor alterations and survival in veterans who develop metastatic castrate resistant prostate cancer.
269 Background: Despite the increasing use of comprehensive genetic tumor profiling, molecular data has limited influence in determining treatment. Howeve...
Real-world assessment of clinical outcomes of first-line treatment in metastatic papillary renal cell carcinoma.
471 Background: Papillary renal cell carcinoma (pRCC) is the most common non-clear cell RCC (nccRCC) representing up to 15% of RCC. First line (1L) phase...
Characterizing immunogenicity of <i>MYC-</i> amplified, metastatic prostate cancer as reflected by the recovery rates of adaptive immune receptor recombinations from RNAseq files.
241 Background: In prostate cancer, identifying biomarkers to predict patients who are at higher risk for metastatic disease remains a key question. The i...
Additional efficacy and safety outcomes and an exploratory analysis of the impact of pathological complete response (pCR) on long-term outcomes from NIAGARA.
659 Background: In the phase 3 NIAGARA study of patients (pts) with muscle-invasive bladder cancer (MIBC), perioperative durvalumab (D) plus neoadjuvant c...
Local definitive therapy (LDT) utilization patterns and outcomes in chromophobe renal cell carcinoma (chRCC) with metachronous metastasis: A multi-institution study.
503 Background: LDTs, including surgical resection, radiation treatment and ablation/embolization, can be employed to achieve a disease-free state in indo...
Phase I trial of hypofractionated radiotherapy and pembrolizumab in the treatment of muscle invasive/metastatic bladder cancer: Results of the PLUMMB trial.
756 Background: The objective of the PLUMMB trial (NCT02560636) was to assess the safety, tolerability and efficacy of the addition of the anti-PD1 antibo...
The effect of circadian rhythm–based medication timing adjustments on the efficacy and safety of novel hormonal therapy.
TPS277 Background: Neoadjuvant hormonal therapy (NHT) serves as the primary treatment approach for metastatic hormone-sensitive prostate cancer (mHSPC) by...